Optimal antithrombotic therapy after transcatheter aortic valve replacement in patients with atrial fibrillation.
Qingchun ZengZhendong ChengYi XiaRui ChengAilian OuXinrui LiXingbo XuYu-Li HuangDingli XuPublished in: Therapeutic advances in chronic disease (2020)
Atrial fibrillation (AF) is prevalent in patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Depending on the timing of AF detection, it is usually categorized as pre-existing AF or new-onset AF. Antiplatelet therapy, rather than a vitamin K antagonist, may be considered as the primary treatment for patients without an indication for oral anticoagulants who undergo TAVR. However, the optimal postprocedural antithrombotic regimen for patients with AF undergoing TAVR remains unknown. In this review, we briefly introduce the management strategies of antithrombotic therapy and list the evidence from related studies to elucidate the optimal antithrombotic management for patients with AF undergoing TAVR.
Keyphrases
- atrial fibrillation
- transcatheter aortic valve replacement
- aortic stenosis
- oral anticoagulants
- ejection fraction
- aortic valve
- aortic valve replacement
- percutaneous coronary intervention
- catheter ablation
- transcatheter aortic valve implantation
- left atrial
- antiplatelet therapy
- left atrial appendage
- direct oral anticoagulants
- heart failure
- left ventricular
- end stage renal disease
- acute coronary syndrome
- chronic kidney disease
- newly diagnosed
- coronary artery disease
- prognostic factors
- mitral valve
- real time pcr